Long GV, Carlino MS, Au-Yeung G, Spillane AJ, et al. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial. Nat Med 2024 Jun 21. doi: 10.1038/s41591-024-03077.
PMID: 38907159